Seaport Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 21.1 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.13B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company’s lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-...